Pharmaceutical company focused on medical dermatology Almirall has signed a multi-target alliance with mRNA/LNP technology platform company etherna to discover and develop new mRNA-based therapies to address severe skin diseases, including non-melanoma skin cancer.
Rigel Pharmaceuticals has entered into a multi-year strategic development collaboration with The University of Texas MD Anderson Cancer Center (MD Anderson) for expanding the assessment of REZLIDHIA (olutasidenib) in acute myeloid leukaemia (AML) and other haematologic cancers.
Phenomic AI (Phenomic) has announced a research collaboration with Astellas Pharma for the development of solid tumour cell therapies.
Biotechnology company Q32 Bio has signed an agreement to merge with Homology Medicines, in an all-stock transaction.
Xentria has received orphan drug designation (ODD) from the European Medicines Agency (EMA) for its anti-TNFα monoclonal antibody, XTMAB-16.
OrsoBio has raised $60m in Series A financing to advance its metabolic portfolio for the treatment of obesity and associated disorders.
Halozyme Therapeutics and Acumen Pharmaceuticals have signed a global collaboration and non-exclusive license agreement for the ENHANZE drug delivery technology in Alzheimer's disease.
US-based Noramco has acquired the Cambrex Drug Product Business Unit, which was formerly known as Halo Pharmaceuticals.
Basilea Pharmaceutica and iNtRON Biotechnology have signed an exclusive evaluation license and option agreement for the potential first-in-class clinical-stage antibacterial agent, tonabacase.
Canadian company PharmaDrug has signed a definitive agreement to acquire Securedose Synthetics, a privately-held pharmaceutical research and development company.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.